Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

  • September 6, 2026

Roivant’s $14 million bet on a pulmonary hypertension drug from Bayer appears to have paid off as the inhaled med aced a phase 2 lung disease study.

Leave A Comment

Fields (*) Mark are Required